Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
IKT 
Inhibikase Therapeutics Inc (IKT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/01/2025: IKT (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8
1 Year Target Price $8
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 81.94% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 07/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 144.97M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 2 | Beta 0.94 | 52 Weeks Range 1.12 - 4.20 | Updated Date 07/1/2025 |
52 Weeks Range 1.12 - 4.20 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.58 |
Earnings Date
Report Date 2025-06-06 | When After Market | Estimate -0.095 | Actual -0.15 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -46.95% | Return on Equity (TTM) -79.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 51860484 | Price to Sales(TTM) 1000000 |
Enterprise Value 51860484 | Price to Sales(TTM) 1000000 | ||
Enterprise Value to Revenue 2.75 | Enterprise Value to EBITDA 0.34 | Shares Outstanding 74341504 | Shares Floating 24869475 |
Shares Outstanding 74341504 | Shares Floating 24869475 | ||
Percent Insiders 13.02 | Percent Institutions 74.22 |
Analyst Ratings
Rating 1 | Target Price 8 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Inhibikase Therapeutics Inc
Company Overview
History and Background
Inhibikase Therapeutics, Inc. (IKT) is a clinical-stage biopharmaceutical company founded to develop therapeutics targeting protein misfolding, leading to neurodegenerative diseases. The company focuses on small-molecule inhibitors of protein translation.
Core Business Areas
- Neurodegenerative Disease Therapeutics: Developing small molecule drugs to treat neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and related disorders.
Leadership and Structure
Dr. Milton Werner is the President and CEO. The company has a board of directors and a management team overseeing research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- Risuteganib (Rezumirad): Phase 2 clinical trials for progressive vision loss associated with dry AMD. Current market size for dry AMD therapies is significant, with unmet medical needs. Competitors include Apellis and Iveric Bio (acquired by Astellas).
- IKT-148009: Clinical stage drug candidate for Parkinson's Disease. Competitors include companies developing symptomatic treatments and disease-modifying therapies for Parkinson's.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with a focus on innovative therapies for unmet medical needs. The neurodegenerative disease market is large and growing due to an aging population.
Positioning
Inhibikase is positioned as a clinical-stage company focused on novel small molecule therapies for neurodegenerative diseases. Competitive advantages may include a unique mechanism of action.
Total Addressable Market (TAM)
The global neurodegenerative disease market is projected to reach hundreds of billions of dollars. IKT aims to capture a portion of this TAM through its targeted therapies.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach
- Clinical-stage pipeline
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- High risk of clinical trial failure
- Dependence on key personnel
- Reliance on external funding
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Orphan drug designation
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Unsuccessful clinical trials
Competitors and Market Share
Key Competitors
- APLS
- ASTL
Competitive Landscape
Inhibikase faces competition from larger, well-established pharmaceutical companies with greater resources. It competes on innovation and addressing unmet needs in specific indications. APLS and ASTL are key competitors in dry AMD treatments.
Growth Trajectory and Initiatives
Historical Growth: Limited historical revenue. Growth is dependent on future clinical trial successes.
Future Projections: Analyst projections are highly variable and contingent on clinical trial outcomes. Revenue is projected upon successful commercialization. Revenue will likely be zero until commercialization.
Recent Initiatives: Advancing clinical trials for lead drug candidates, seeking partnerships, securing funding through equity offerings.
Summary
Inhibikase Therapeutics is a high-risk, high-reward clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases. The company's success hinges on positive clinical trial results, securing partnerships, and managing its cash burn. Key risks include clinical trial failure, competition, and regulatory hurdles. The company is working well in advancing its pipeline but needs to secure financial strength.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, SEC filings, ClinicalTrials.gov, Analyst reports, Company Website
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investing in biopharmaceutical companies is highly speculative and carries significant risks. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inhibikase Therapeutics Inc
Exchange NASDAQ | Headquaters Atlanta, GA, United States | ||
IPO Launch date 2020-12-23 | CEO & Director Mr. Mark T. Iwicki | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | Website https://www.inhibikase.com |
Full time employees 15 | Website https://www.inhibikase.com | ||
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.